SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Discussion centers on Compounds reported institutional-market push, leadership changes, and planned V4 and tokenized-asset development. Traders are divided between buying the weakness on expectations of a turnaround and frustration that COMP continues to lag other crypto assets.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, unexplained XCN price spike and volatile swings are driving attention, with traders highlighting a large candle and a brief pump. Some are buying dips and expecting a rebound, while others call the move a pump-and-dump and question whether gains will hold.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Fresh Phase 3 biliary-tract cancer results for ivonescimab showing a survival benefit over standard treatment are driving attention, alongside anticipation of the separate November 14 FDA decision for the drug in EGFR-mutated lung cancer. Traders are encouraged by the data but debate how much weight to give China-based interim results and whether the positive news will overcome recent share-price weakness.

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Natera Inc

Nateras repeated 52-week highs and strong momentum are drawing attention, with bulls pointing to demand for its genetic and oncology diagnostics, including MRD testing, while others caution that the run looks overextended. Billing-settlement updates are also circulating, but some traders view them as secondary to test-volume growth.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is drawing attention amid volatile price action and renewed breakout talk, with traders split on whether the bounce can hold or fade. Bulls cite the planned CashVM/Layla upgrade as a potential catalyst for greater programmability, while skeptics continue to question BCHs utility and momentum.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

A sharp QNT rebound has fueled breakout and short-squeeze chatter, with traders tying the move to Quants Clearing House On-Chain Money Initiative and prospects for tokenized bank deposits. Bulls see institutional adoption and limited supply as potential tailwinds, while skeptics question whether the software partnership will create direct demand for QNT tokens.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Cantons institutional adoption and real-world-asset tokenization are driving attention, with traders highlighting DTCCs planned tokenization activity and additions such as Visa as a Super Validator. Optimism about the networks prospects is tempered by debate over CCs muted price performance, token emissions and unlocks, and whether network usage will translate into value for holders.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Discussion centers on concern that the proposed 2027 CMS reimbursement for DefenCath may be less favorable than hoped, leaving growth dependent on broader payer coverage and legislative or policy changes. Traders also debate DefenCaths real-world performance against ClearGuard, with some viewing the data as a threat to adoption and others arguing the products are not directly comparable.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for its prolonged, range-bound trading, with traders repeatedly discussing consolidation and nearby support and resistance. Some holders are accumulating and anticipating a breakout, while others expect further weakness and question the tokens utility.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Concerns about AI-driven cyber threats and newly highlighted software vulnerabilities are boosting cybersecurity stocks, with traders pointing to Oktas identity-security role as AI agents expand the need to control access. Bulls are cheering the breakout and sector strength, while skeptics argue the rally has outrun Oktas modest growth and valuation is stretched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? 

Equity

The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence. 


ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside

Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.


Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough

The breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.

Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?

Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.

Why Did BNTX Stock Tumble 17% Pre-Market Today? 

BioNTech co-founders Ugur Sahin and  Özlem Türeci are set to leave the company to head the new venture.  


IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

AI Scare Back in the Market: ETFs That Stayed Steady

AI fears rattled markets as IBM sank and tech slid, but ETFs like OIH, BWET, IDNA and HDGE stayed resilient, gaining even as major indexes fell.

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review

The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.


Why Is ALVO Stock Rising Pre-Market Today?

The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.

iShares Trust - iShares Genomics Immunology and Healthcare ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Iovance shares hit a two-year high of $15.30 after the company raised its 2026 revenue forecast to $410 million-$420 million.</li><li>JPMorgan initiated coverage of AbCellera with an Overweight rating and $17 price target, citing promising ABCL635 data.&nbsp;</li><li>CrowdStrike shares hit a record $267.69 after the company announced plans to bring its Falcon platform to the OpenAI Marketplace.</li></ul>Iovance Biotherapeutics (<a class="mention" data-mention="$IOVA" data-symbol-id="IOVA" href="https://stocktwits.com/symbol/IOVA" target="_blank">IOVA</a>), AbCellera Biologics (ABCL) and CrowdStrike Holdings (CRWD) hit fresh 52-week highs on Tuesday as investors responded to stronger business outlooks, analyst support and AI-driven cybersecurity expansion.&nbsp;Iovance’s stock jumped 31%, while AbCellera and CrowdStrike stocks gained over 6% and 1%, respectively.&nbsp;<h2 class="st-heading-2">Iovance Biotherapeutics Raises Outlook</h2><a href="https://stocktwits.com/symbol/IOVA">Iovance stock</a> reached a two-year high of $15.30 after the biotech company raised its 2026 revenue outlook. The company now sees full-year sales between $410 million and $420 million, representing growth of almost 60% from last year and coming in well ahead of the consensus estimate of $407 million, according to Fiscal.ai data.The improved outlook reflects stronger commercial demand for Amtagvi, the company's tumor-infiltrating lymphocyte therapy for metastatic melanoma. The stronger business outlook also prompted H.C. Wainwright analyst Joseph Pantginis to lift his price target to $20 from $9 while keeping a ‘Buy’ rating.On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">AbCellera Gains JPMorgan Backing</h2><a href="https://stocktwits.com/symbol/ABCL">AbCellera stock</a> jumped to a four-year high of $15 as JPMorgan began covering the biotechnology company with an ‘Overweight’ rating and a $17 price target, describing the business as approaching a "major value inflection point."The firm pointed to clinical results from ABCL635, AbCellera's internal program targeting NK3R protein to address menopausal hot flashes. JPMorgan highlighted the candidate's combination of efficacy, safety, and dosing convenience.&nbsp;The firm also cited AbCellera's broad collection of pharmaceutical partnerships as support for its technology platform and noted that those relationships can help offset the company's operating expenses. Retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">CrowdStrike Expands Into OpenAI Marketplace</h2><a href="https://stocktwits.com/symbol/CRWD">CrowdStrike stock</a> climbed to a record high of $267.69 after the cybersecurity company announced plans to bring its Falcon platform to the OpenAI Marketplace.The move connects CrowdStrike's cloud-based security and threat intelligence capabilities with OpenAI's enterprise AI ecosystem. The integration will give business customers greater security while helping automate responses to potential threats. Investors expect the growing use of AI agents to increase demand for security tools.&nbsp;However, retail sentiment around the stock remained in ‘bearish’ territory.&nbsp;So far this year, <a class="mention" data-mention="$IOVA" data-symbol-id="IOVA" href="https://stocktwits.com/symbol/IOVA" target="_blank">IOVA</a>, ABCL and CRWD stocks have gained between 124% and 429%.Also see:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rum-stock-ticks-higher-overnight-analyst-sees-upside-as-13-billion-anthropic-deal-sets-off-ai-pivot/cZMnABwRBWV">RUM Stock Ticks Higher Overnight: Analyst Sees 94% Upside As $13B Anthropic Deal Sets Off AI Pivot</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Iovance Biotherapeutics (IOVA), AbCellera Biologics (ABCL) and CrowdStrike Holdings (CRWD) hit fresh 52-week highs on Tuesday as investors responded to stronger business outlooks, analyst support and AI-driven cybersecurity expansion.

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?

AbCellera Biologics Inc

Crowdstrike Holdings Inc

iShares Genomics Immunology and Healthcare ETF

iShares Expanded Tech-Software Sector ETF

Iovance Biotherapeutics Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

IDNA iShares Genomics Immunology and Healthcare ETF

Fundamentals

Latest IDNA News